Cyclic peptides for treating herpes infections
    1.
    发明授权
    Cyclic peptides for treating herpes infections 失效
    用于治疗疱疹感染的循环肽

    公开(公告)号:US5149778A

    公开(公告)日:1992-09-22

    申请号:US547721

    申请日:1990-07-03

    IPC分类号: A61K38/00 C07K7/56

    摘要: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文公开了具有下式的环肽衍生物:其中A不存在或三肽基Thr <-Gly <-Ala,R1是苄基或在芳环的4位被卤素单取代的苄基的环肽衍生物 ,羟基,低级烷基或低级烷氧基,R 2和R 4各自独立地为氢或低级烷基,R 3为低级烷基或被羟基单取代的低级烷基,R 5为低级烷基,Y为氧代或硫代,Z为羟基或NR 6 R 7,其中R 6 和R 7各自独立地为氢或低级烷基。 该衍生物可用于治疗疱疹感染。

    Cyclic peptides for treating herpes infections
    2.
    发明授权
    Cyclic peptides for treating herpes infections 失效
    用于治疗疱疹感染的循环肽

    公开(公告)号:US5258493A

    公开(公告)日:1993-11-02

    申请号:US853360

    申请日:1992-03-16

    IPC分类号: A61K38/00 C07K7/56 C07K7/54

    CPC分类号: C07K7/56 A61K38/00 Y10S930/27

    摘要: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文公开了具有下式的环肽衍生物:其中A不存在或三肽基Thr <-Gly <-Ala,R 1为苄基或在芳环的4位被卤素单取代的苄基的环肽衍生物 ,羟基,低级烷基或低级烷氧基,R 2和R 4各自独立地为氢或低级烷基,R 3为低级烷基或被羟基单取代的低级烷基,R 5为低级烷基,Y为氧代或硫代,Z为羟基或NR 6 R 7,其中R 6 和R 7各自独立地为氢或低级烷基。 该衍生物可用于治疗疱疹感染。

    Antiherpes pentapeptide derivatives having a substituted aspartic acid
side chain
    3.
    发明授权
    Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain 失效
    具有取代的天冬氨酸侧链的反相五肽衍生物

    公开(公告)号:US5502036A

    公开(公告)日:1996-03-26

    申请号:US208168

    申请日:1994-03-09

    摘要: Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH CH.sub.2 C(O)--Y!--C(W.sup.3)--NH--CR.sup.6 -- CR.sup.7 (R.sup.8)--COOH!--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R.sup.1 is hydrogen, alkyl or phenylalkyl, R.sup.2, R.sup.4 and R.sup.10 are selected from amino acid or derived amino acid residues, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are hydrogen or alkyl or R.sup.7 and R.sup.8 are joined to form a cycloalkyl, W.sup.1, W.sup.2, W.sup.3 and W.sup.4 are oxo or thioxo, Y is, for example, an alkoxy or a mono or disubstituted amino, and Z is a terminal group, for example, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文公开了式X-NR1-CH(R2)-C(W)-NH-CR3(R4)-C(W2)-NR5-CH [CH2C(O)-Y] -C(W3)的五肽衍生物 -NH-CR 6 - [CR 7(R 8)-COOH] -C(W 4)-NH-CR 9(R 10)-Z其中X是末端基团,例如烷酰基或苯基烷酰基,R 1是氢,烷基或苯基烷基, R2,R4和R10选自氨基酸或衍生的氨基酸残基,R3,R5,R6,R7,R8和R9是氢或烷基或R7和R8连接形成环烷基,W1,W2,W3和W4分别为 氧代或硫代,Y是例如烷氧基或单或二取代的氨基,Z是末端基团,例如COOH或CH 2 OH。 该衍生物可用于治疗疱疹感染。

    Isoquinolines useful as analgesics
    4.
    发明授权
    Isoquinolines useful as analgesics 失效
    异喹啉可用作镇痛药

    公开(公告)号:US6034097A

    公开(公告)日:2000-03-07

    申请号:US930867

    申请日:1997-10-06

    申请人: John DiMaio Wuyi Wang

    发明人: John DiMaio Wuyi Wang

    摘要: The present invention is directed to compounds that act as analgesics and that have the structure of formula (I): ##STR1## wherein; Z is ##STR2## wherein, n is 1 or 2, and R.sub.0 is C.sub.6-12 aryl or C.sub.7-8 aralkyl; orR.sub.1 is selected from the group consisting of hydrogen; --NH--C.sub.1-6 alkyl; C.sub.1-6 alkyl; C.sub.6-12 aryl; C.sub.7-18 aralkyl; arginyl; and R.sub.30 NHC(.dbd.NH)--, wherein R.sub.30 is hydrogen, C.sub.6-12 aryl, C.sub.7-18 aralkyl, or C.sub.1-6 alkyl;R.sub.2 is hydrogen; C.sub.1-6 alkyl; or OH;R.sub.3 is C.sub.6-12 aryl; C.sub.7-18 aralkyl; --CH.sub.2 --C.sub.6 H.sub.2 R.sub.8 R.sub.9 ;or --CH.sub.2 --OHC.sub.6 HR.sub.8 R.sub.9, wherein each of R.sub.8 and R.sub.9 is independently, or hydrogen;R.sub.4 C.sub.6-12 aryl; C.sub.7-18 aralkyl; C.sub.1-12 alkyl; or a substituted or unsubstituted cyclohexyl;R.sub.5 is C.sub.1-6 alkyl; hydrogen; OH; halogen; SH; NO.sub.2 ; NH.sub.2 ; --NH--C.sub.1-6 alkyl; NH.sub.2 C (.dbd.NH--; NH.sub.2 C (.dbd.NH)--NH--; COOR.sub.31, wherein, R.sub.31 is hydrogen, or C.sub.1-6 alkyl;X is CH.sub.2 NHC(O)--; CH.sub.2 NHC(O)O; --C(O)NH--; or CH.sub.2 NH--; andL is a C.sub.1-12 alkylene chain which can be substituted with at least one substituent selected from the group consisting of; a C.sub.3 -C.sub.12 cycloalkyl containing at least one heteroatom; C.sub.1-6 alkyl; OR.sub.31 ; --NHC(O)R.sub.33 ; --OC(O)R.sub.34 --NHR.sub.35 wherein; and NR.sub.6 R.sub.7 ;with the proviso that when R.sub.5 is hydrogen, Z is ##STR3## and X is --C(O)NH--, or --CH.sub.2 NH--, then L is a C.sub.1-12 alkyl chain substituted with at least one substituent selected from the group consisting of; a C.sub.3 -C.sub.12 cycloalkyl containing at least one heteroatom; C.sub.1-6 alkyl; OR.sub.31 ; SR.sub.32 ; --NHC(O)R.sub.33 ; --OC(O)R.sub.34, --NHR.sub.35 ; and NR.sub.6 R.sub.7.

    摘要翻译: PCT No.PCT / SE97 / 00315 Sec。 371日期:1997年10月6日 102(e)日期1997年10月6日PCT 1997年2月25日提交PCT公布。 第WO97 / 31940号公报 日期:1997年9月4日本发明涉及作为止痛剂的具有式(I)结构的化合物:其中: Z是其中n是1或2,R 0是C 6-12芳基或C 7-8芳烷基; 或R 1选自氢; -NH-C 1-6烷基; C 1-6烷基; C6-12芳基; C7-18芳烷基; 精氨酰 和R 30 NHC(= NH) - ,其中R 30是氢,C 6-12芳基,C 7-18芳烷基或C 1-6烷基; R2是氢; C 1-6烷基; 或OH; R3为C6-12芳基; C7-18芳烷基; -CH 2 -C 6 H 2 R 8 R 9或-CH 2 -OH C 6 H 8 R 9,其中R 8和R 9各自独立地是氢或氢; R4 C6-12芳基; C7-18芳烷基; C 1-12烷基; 或取代或未取代的环己基; R5是C1-6烷基; 氢; 哦; 卤素; SH; NO2; NH2; -NH-C 1-6烷基; NH 2 C(= NH-; NH 2 C(= NH)-NH-; COOR 31,其中R 31是氢或C 1-6烷基; X是CH 2 NHC(O) - ; CH 2 NHC(O)O; -C(O) ;或CH 2 NH-;并且L是可以被至少一个选自以下的取代基取代的C 1-12亚烷基链:包含至少一个杂原子的C 3 -C 12环烷基; C 1-6烷基; OR 31; -NHC (O)R 33; -OC(O)R 34 -NHR 35,其中;和NR 6 R 7;条件是当R 5为氢时,Z为且X为-C(O)NH-或-CH 2 NH-,则L为C1 -12烷基链,其被至少一个选自以下的取代基取代:含有至少一个杂原子的C 3 -C 12环烷基; C 1-6烷基; OR 31; SR 32; -NHC(O)R 33; -OC(O)R 34 ,-NHR 35;和NR 6 R 7。

    Cold Wax Ear Hair Removal Instrument
    5.
    发明申请
    Cold Wax Ear Hair Removal Instrument 审中-公开
    冷蜡耳脱毛仪

    公开(公告)号:US20090163933A1

    公开(公告)日:2009-06-25

    申请号:US11961002

    申请日:2007-12-20

    申请人: John DiMaio

    发明人: John DiMaio

    IPC分类号: A61B17/50

    CPC分类号: A61B17/50

    摘要: An ear hair removal instrument including a head, at least a portion of which its outer surface is covered with cold wax. The head is shaped and sized to be receivable in the outer ear while preventing insertion into the middle ear. A handle is mounted at its distal end to the head. In use, the head of the instrument is inserted in the outer ear so that the cold wax disposed on the head comes into contact with the ear hair. While disposed in the outer ear, the ear hair in contact with the cold wax is extracted from its follicles by simultaneously rotating and pulling the instrument.

    摘要翻译: 耳毛去除器具包括头部,其至少一部分外表面被冷蜡覆盖。 头部的形状和尺寸设计成能够接收在外耳中,同时防止插入中耳。 手柄在其远端安装到头部。 在使用中,仪器的头部插入外耳中,使得头部上的冷蜡与耳毛接触。 当设置在外耳中时,通过同时旋转和拉动器械从与其冷冻的蜡接触的耳毛被提取出来。

    Thrombin inhibitors based on the amino acid sequence of hirudin
    6.
    发明授权
    Thrombin inhibitors based on the amino acid sequence of hirudin 失效
    基于水蛭素氨基酸序列的凝血酶抑制剂

    公开(公告)号:US6060451A

    公开(公告)日:2000-05-09

    申请号:US406142

    申请日:1995-03-20

    CPC分类号: C07K14/815 A61K38/00

    摘要: A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and acidic character of amino acids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-acetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 carbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of D-configuration. The compounds are useful in the treatment of thrombotic disorders.

    摘要翻译: 一种凝血酶抑制剂,其包含与负责蛋白水解的凝血酶的催化位点相互作用的第一大体积疏水部分,和至少保持天然水蛭素氨基酸55至60在C末端非催化区域的疏水和酸性特征的第二部分 N-乙酰水蛭素45-65。 第一和第二部分之间的链长为至少10个碳原子的二价接头部分。 连接第一个庞大的疏水部分和连接体是拟肽键。 优选地,大体积的疏水部分包含至少一个D-构型的氨基酸。 该化合物可用于治疗血栓形成障碍。